Compare Dow Jones Industrial Average ETF (DIA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Smith & Nephew plc — how do they compare? Dow Jones Industrial Average ETF trades at $524.84, while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Smith & Nephew plc pays a 2.62% dividend while Dow Jones Industrial Average ETF pays none, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| DIA | SNN | |
|---|---|---|
52-Week High | $530.02 | $38.70 |
52-Week Low | $435.72 | $28.73 |
Market Cap | — | $12.40B |
Sector | — | Health |
Enterprise Value | — | $15.17B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average's 30 blue-chip stocks, providing diversified exposure to large-cap U.S. equities. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting its tech weighting. Dividend distributions continue with scheduled payouts through mid-2026.
Outlook remains positive given the Dow's 8% year-to-date gain and DIA's 10-year average annual return of 13.3%. Key opportunities include broad market exposure and dividend income, while risks involve Fed policy shifts and concentration in cyclical sectors. Analyst sentiment is favorable due to the ETF's low-cost structure and historical performance.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
